Overview

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

Status:
Completed

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

This study is to determine the feasibility of postoperative platinum-based chemotherapy plus adjuvant and maintenance bevacizumab after neoadjuvant chemotherapy followed by interval surgery in patients with extensive stage IIIC or IV ovarian, tubal, and peritoneal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Chang Gung Memorial Hospital

Collaborators:

Asian Gynecologic Oncology Group
Hoffmann-La Roche
Taiwanese Gynecolgic Oncology Group

Treatments:

Bevacizumab